PDCD1 and cancer: In this study, we showed that cancer-targeting NIR-PIT converted a minimally immunogenic tumor (MOC2-luc) into a highly immunogenic tumor by increasing the number and density of activated CD8+ T cells infiltrating into the tumor, leading to improved efficacy of the anti-PD-1 immune-checkpoint inhibitor.